Archived - For the Public - Important Safety Information on IRESSA (gefitinib) - AstraZeneca Canada Inc.
- Starting date:
- April 10, 2007
- Posting date:
- May 14, 2007
- Type of communication:
- Public Communication
- Source of recall:
- Health Canada
- General Public
- Identification number:
This is duplicated text of a letter from AstraZeneca Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
Health Canada Endorsed Important Safety Information on IRESSA® (gefitinib)
April 10, 2007
Subject: Use of IRESSA® in patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) failed to prolong survival and increased bleeding events.
AstraZeneca Canada Inc., in consultation with Health Canada, would like to inform all patients in the IRESSA Patient Registry (IPR) Program of new information from a clinical trial on the use of IRESSA in patients who have head and neck cancer. It should be noted that head and neck cancer is not an approved use for IRESSA, but patients with this diagnosis may be participating in the IPR Program if benefiting from therapy.
In a large clinical trial in patients with head and neck cancer, patients received IRESSA 250 mg, IRESSA 500 mg or methotrexate chemotherapy. The purpose of the study was to compare how long head and neck cancer patients lived if they were treated with IRESSA or methotrexate. Results from the study showed that neither dose of IRESSA prolonged life compared with patients receiving methotrexate.
Also in this study, it was found that more patients treated with IRESSA, when compared to methotrexate, suffered from bleeding from the cancer in their head and neck as a possible side effect. 9% (14/158) of patients taking IRESSA 250 mg and 11% (19/166) of patients taking IRESSA 500 mg suffered bleeding from their head and neck cancer, compared to 2% (3/159) of patients taking methotrexate. In most of these patients the bleeding was mild to moderate and got better. In some rare cases, patients died from the bleeding. There were 36 patients who had bleeding in the study, and 3 patients (all taking IRESSA) died from the bleeding.
As a patient in the IRESSA Patient Registry program, Health Canada, in collaboration with AstraZeneca, has requested that you be made aware of these new study results. It is recommended that you review the use of IRESSA in your treatment plan with your own physician.
IRESSA will continue to be available to patients currently benefiting from treatment who have been prescribed IRESSA as of October 31, 2006, and were registered into the IRESSA Patient Registry as of December 31, 2006. Please contact the IRESSA Patient Registry at 1-866-473-7720 for more details.
If you are participating in a clinical trial using IRESSA to treat head and neck cancer and receive IRESSA directly from your physician, your case should be reviewed with your physician, as therapy may need to be discontinued.
AstraZeneca Canada Inc.
1004 Middlegate Road
Mississauga, ON L4Y 1M4
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: 613-957-0337 or Fax: 613-957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
For other inquiries related to this communication, please contact Health Canada at:
Therapeutics Products Directorate - Bureau of Metabolism, Oncology and Reproductive Sciences (BMORS)
Should you have any questions or require additional information about IRESSA®, please contact your health care provider (physician, nurse or pharmacist) or AstraZeneca Medical Information at 1-800-668-6000 (English) and/or 1-800-461-3787 (French).
IRESSA® and the AstraZeneca logo are trade-marks of the AstraZeneca group of companies.